Brief: TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-200-A0201
06/06/2023 12:25
June 6 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR TSC-200-A0201 TARGETING HPV16 TO TREAT
SOLID TUMORS
Source text for Eikon: ID:nGNX81R4Gy
Further company coverage: TCRX.O
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing